<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20090810002324N16</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-06-06</date_registration>
      <primary_sponsor>Iran University of Medical Sciences</primary_sponsor>
      <public_title>Aromatherapy and orientation tour on anxiety, stress and depressed mood</public_title>
      <acronym></acronym>
      <scientific_title>The effect of aromatherapy and orientation tour on anxiety, stress, and depressed mood in mothers of preterm infants</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2020-07-31</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>126</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/47469</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Not randomized, Blinding: Single blinded, Placebo: Used, Assignment: Parallel, Purpose: Supportive, Blinding description: All questionnaires at all stages, will be gathered by the research assistant who is unaware of the groups' allocation.</study_design>
      <phase>N/A</phase>
      <hc_freetext>The state and trait anxiety, stress, depressed mood.</hc_freetext>
      <i_freetext>Intervention 1: Orientation tour: At first, four drops of distilled water, as a placebo, will be dripped on a pad and attached to the mother’s collar of clothes. The mother will inhale it normally for 30 minutes. After removing the pad, the mother and the researcher will enter into the neonatal intensive care unit (NICU) for the first time. Then the orientation tour will be individually held for the mother in a 30- minute section. The mother will be familiarized with the NICU by brief and understandable explanations about equipment such as ventilator, incubator, phototherapy set, pulse oximeter, monitor, warmer and other devices. Employees will be introduced and rules in the NICU will also be explained. At the end of intervention’s day, the mothers of this group will re-inhale pad which drips with four drops of distilled water, for 30 minutes before bedtime. Intervention 2: Aromatherapy and Orientation tour: At first, four drops of 2% orange essence (made by the Barij Essence Pharmaceutical Company) will be dripped on a pad and attached to the mother’s collar of clothes. The mother will inhale it normally for 30 minutes. After removing the pad, the mother and the researcher will enter into the neonatal intensive care unit (NICU) for the first time. Then the orientation tour will be individually held for the mother in a 30- minute section. The mother will be familiarized with the NICU by brief and understandable explanations about equipment such as ventilator, incubator, phototherapy set, pulse oximeter, monitor, warmer and other devices. Employees will be introduced and rules in the NICU will also be explained. At the end of intervention’s day, the mothers of this group will re-inhale pad, which drips with four drops of 2% orange essence, for 30 minutes before bedtime. Intervention 3: Control group: The control group will meet their baby for the first time in the usual way, and all schedules for completing the questionnaires in this group will be included. None of the aromatherapy and orientation tour methods will be performed for this group.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is Decisions will be made in the future</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Maryam Keshavarz</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>School of Nursing &amp; Midwifery, Rashid Yasemi st., Valiasr St., Tehran, IRAN</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1996713883</zip>
        <telephone>+98 21 4365 1813</telephone>
        <email>Keshavarz.m@iums.ac.ir</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Maryam Keshavarz</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>School of Nursing &amp; Midwifery, Rashid Yasemi st., Valiasr St., Tehran, IRAN</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1996713883</zip>
        <telephone>+98 21 4365 1813</telephone>
        <email>keshavarz.m@iums.ac.ir</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Iranian primiparous women
Single Pregnancy
Pregnancy age 30 - 36 weeks
First entry into the neonatal intensive care unit
Ability to at least read and write
Respiratory distress in the newborn</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>40 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Substance-abusing (cigarettes, alcohol, and psychotropics)
The problem of smell, respiratory diseases, sensitivity to the orange aroma
Use of herbal oils and sedatives at least six weeks before the intervention
Mental illness (according to the personal reporting)
History of recurrent miscarriage or infertility
Congenital anomaly in newborn
The referred newborn from other hospitals
Apgar score of 6 or less at minutes 5</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Prevention</i_code>
      <i_code>Prevention</i_code>
      <i_code>N/A</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Orientation tour: At first, four drops of distilled water, as a placebo, will be dripped on a pad and attached to the mother’s collar of clothes. The mother will inhale it normally for 30 minutes. After removing the pad, the mother and the researcher will enter into the neonatal intensive care unit (NICU) for the first time. Then the orientation tour will be individually held for the mother in a 30- minute section. The mother will be familiarized with the NICU by brief and understandable explanations about equipment such as ventilator, incubator, phototherapy set, pulse oximeter, monitor, warmer and other devices. Employees will be introduced and rules in the NICU will also be explained. At the end of intervention’s day, the mothers of this group will re-inhale pad which drips with four drops of distilled water, for 30 minutes before bedtime.</i_keyword>
      <i_keyword>Aromatherapy and Orientation tour: At first, four drops of 2% orange essence (made by the Barij Essence Pharmaceutical Company) will be dripped on a pad and attached to the mother’s collar of clothes. The mother will inhale it normally for 30 minutes. After removing the pad, the mother and the researcher will enter into the neonatal intensive care unit (NICU) for the first time. Then the orientation tour will be individually held for the mother in a 30- minute section. The mother will be familiarized with the NICU by brief and understandable explanations about equipment such as ventilator, incubator, phototherapy set, pulse oximeter, monitor, warmer and other devices. Employees will be introduced and rules in the NICU will also be explained. At the end of intervention’s day, the mothers of this group will re-inhale pad, which drips with four drops of 2% orange essence, for 30 minutes before bedtime.</i_keyword>
      <i_keyword>Control group: The control group will meet their baby for the first time in the usual way, and all schedules for completing the questionnaires in this group will be included. None of the aromatherapy and orientation tour methods will be performed for this group.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>The score of state anxiety. Timepoint: One hour before the mother's first visit to the neonatal intensive care unit (NICU), an hour after leaving the ward, Twenty-four hours after the intervention. Method of measurement: The state anxiety of Spielberger questionnaire.</prim_outcome>
      <prim_outcome>The score of trait anxiety. Timepoint: One hour before the mother's first visit to the NICU, an hour after leaving the ward, Twenty-four hours after the intervention. Method of measurement: The trait anxiety of Spielberger questionnaire.</prim_outcome>
      <prim_outcome>The score of parental stress. Timepoint: Twenty-four hours after the intervention. Method of measurement: The Parental Stressor Scale: Neonatal Intensive Care Unit (PSS: NICU).</prim_outcome>
      <prim_outcome>The score of depressed mood in the Profile of Mood States Questionnaire (POMS) (McNair). Timepoint: One hour before the mother's first visit to the NICU, twenty-four hours after the intervention. Method of measurement: Depressed mood in the Profile of Mood States Questionnaire (POMS) (McNair).</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Iran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-05-27</approval_date>
        <contact_name>Ethic committee of Iran University of Medical sciences</contact_name>
        <contact_address>Iran University of Medical Sciences, Milad Tower, Hemmat Highway, Tehran, Iran Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
